A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

Psychedelic stocks are gaining attention as new ways to treat mental illnesses like depression and post-traumatic stress disorder (PTSD). Companies in the niche use substances like psilocybin to ...

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 met the primary endpoint in a Phase 3 trial for treatment-resistant ...

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS 1 with a mean difference of -3.6 ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 ...